

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/028,018	12/21/2001	Mark G. Erlander	485772004300	2946
25225 75	90 10/15/2003		EXAMINER	
MORRISON & FOERSTER LLP			ZEMAN, MARY K	
3811 VALLEY CENTRE DRIVE SUITE 500		ART UNIT	PAPER NUMBER	
SAN DIEGO, CA 92130-2332			1631	

DATE MAILED: 10/15/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/028,018	ERLANDER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Mary K Zeman	1631				
Th MAILING DATE of this communication app ars on the cov r sheet with the correspondenc address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	i6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	ely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on						
_	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>1-29</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
<u> </u>	7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-29</u> are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
		• •				
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1)	5) Notice of Informal Page	(PTO-413) Paper No(s) atent Application (PTO-152)				
District and Trademark Offi						

Application/Control Number: 10/028,018

Art Unit: 1631

This application contained misnumbered claims: Two different sets of claims were numbered 14 and 15. The claims have been renumbered as per Rule 1.126. The second claim 14 is now claim 16. The second claim 15 is now claim 17. The claim originally submitted as claim 16 is now claim 18, etc. Claims 1-29 are now pending. Applicant is encouraged to double check their own numbering before the submission of any amendments.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-6, drawn to an array comprising more than 1 gene from any of Tables 2-5, classified in class 536, subclass 23.1.
- II. Claims 7-12, drawn to an array comprising more than one gene from Table 1 orTable 6, classified in class 536, subclass 23.1.
- III. Claim 13, drawn to an array comprising more than one gene from Table 7, classified in class 536, subclass 23.1.
- IV. Claim 14, drawn to an array comprising more than one gene from Table 8, classified in class 536, subclass 23.1.
- V. Claims 15-21, drawn to a method of determining the stage of breast cancer using more than one gene correlated with different stages of breast cancer, classified in class 435, subclass 6.
- VI. Claims 22-27, drawn to methods of determining the stage of breast cancer using genes capable of discriminating between stages of breast cancer, classified in class 435, subclass 6.
- VII. Claim 28, drawn to methods of determining the treatment for a patient by staging their breast cancer, classified in class 514, subclass 12+.
- VIII. Claim 29, drawn to methods of identifying genes that discriminate between stages of breast cancer, classified in class 702, subclass 19.

The inventions are distinct, each from the other because of the following reasons:

Each of product Groups I-IV are separate and distinct as each array comprises differing genes. As such they are different biochemically, structurally and functionally. Each of the

Application/Control Number: 10/028,018

Art Unit: 1631

methods of groups V-VIII are independent and distinct as they are differing methods using differing starting materials, having differing steps, and leading to differing goals. The product groups of Inventions I-IV can be separated from the method groups of V-VIII, as none of the products is specifically used in any of the methods, and the products can be used for other processes, such as identifying human tissue samples. Further, the methods do not require the use of an array, and can be done with polynucleotides in a test tube. Each group would require a non-coextensive literature search. As such, it would pose a serious burden upon the examiner if the inventions were not restricted.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined

Art Unit: 1631

claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (703) 305-7133.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at (703) 308-4028.

The Official fax number for this Art Unit is: (703) 872-9306

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the TC1600 Receptionist whose telephone number is (703) 308-0196.

mkz 10/10/03

> MARY K. ZEMAN PRIMARY EXAMINED